Publication | Closed Access
Reticulum-Cell Sarcoma
67
Citations
0
References
1970
Year
PathologyTreatment VerificationRadiation MedicineOncologyConnective TissueRadiopharmaceutical TherapyRadiation Therapy PlanningClinical Radiation OncologyRadiation OncologyNuclear MedicineCancer ResearchRadiologyHealth SciencesRadiological SciencesRadiation TherapyRadionuclide TherapyRadiologic ImagingReticulum-cell SarcomaHead And Neck CancerMedicineExtreme Radiosensitivity Presents
When reticulum-cell sarcoma originates in bone, radioresistant tumors are seen; unless good evidence of extreme radiosensitivity presents, a dose of 4,500–5,500 rads in twenty to thirty-five days should be administered. When disease originates in connective tissue, both radioresistant and radiosensitive tumors may appear; dosage is similar to that for bone. Tumors originating in lymph nodes or the gastrointestinal tract are almost always radiosensitive; dose will vary according to position of disease in the body. Tumors of the head and neck are highly curable but require 5,000–6,500 rads in twenty-five to thirty-five days.